Hyperbilirubinemia and transcutaneous bilirubinometry

Samar N. El-Beshbishi, Karen Shattuck, Amin A. Mohammad, John R. Petersen

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

BACKGROUND: Neonatal jaundice or hyperbilirubinemia is a common occurrence in newborns. Although most cases of neonatal jaundice have a benign course, severe hyperbilirubinemia can lead to kernicterus, which is preventable if the hyperbilirubinemia is identified early and treated appropriately. CONTENT: This review discusses neonatal jaundice and the use of transcutaneous bilirubin (TcB) measurements for identification of neonates at risk of severe hyperbilirubinemia. Such a practice requires appropriate serial testing and result interpretation according to risk level from a nomogram that provides bilirubin concentrations specific for the age of the neonate in hours. In this context, we have evaluated the potential impact on clinical outcome and limitations of TcB methods in current use. SUMMARY: TcB measurement is a viable option in screening neonates to determine if they are at risk for clinically significant hyperbilirubinemia. Total serum bilirubin should be measured by a clinical laboratory if a newborn is shown to be at higher risk for clinically significant hyperbilirubinemia. In addition, external quality assessment to identify biases and operator training issues should be part of any TcB monitoring program.

Original languageEnglish (US)
Pages (from-to)1280-1287
Number of pages8
JournalClinical Chemistry
Volume55
Issue number7
DOIs
StatePublished - Jul 1 2009

Fingerprint

Hyperbilirubinemia
Bilirubin
Neonatal Jaundice
Neonatal Hyperbilirubinemia
Kernicterus
Clinical laboratories
Nomograms
Screening
Monitoring
Testing
Serum

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

El-Beshbishi, S. N., Shattuck, K., Mohammad, A. A., & Petersen, J. R. (2009). Hyperbilirubinemia and transcutaneous bilirubinometry. Clinical Chemistry, 55(7), 1280-1287. https://doi.org/10.1373/clinchem.2008.121889

Hyperbilirubinemia and transcutaneous bilirubinometry. / El-Beshbishi, Samar N.; Shattuck, Karen; Mohammad, Amin A.; Petersen, John R.

In: Clinical Chemistry, Vol. 55, No. 7, 01.07.2009, p. 1280-1287.

Research output: Contribution to journalArticle

El-Beshbishi, SN, Shattuck, K, Mohammad, AA & Petersen, JR 2009, 'Hyperbilirubinemia and transcutaneous bilirubinometry', Clinical Chemistry, vol. 55, no. 7, pp. 1280-1287. https://doi.org/10.1373/clinchem.2008.121889
El-Beshbishi, Samar N. ; Shattuck, Karen ; Mohammad, Amin A. ; Petersen, John R. / Hyperbilirubinemia and transcutaneous bilirubinometry. In: Clinical Chemistry. 2009 ; Vol. 55, No. 7. pp. 1280-1287.
@article{2b106fd0f1134726b8adb6055752cbe7,
title = "Hyperbilirubinemia and transcutaneous bilirubinometry",
abstract = "BACKGROUND: Neonatal jaundice or hyperbilirubinemia is a common occurrence in newborns. Although most cases of neonatal jaundice have a benign course, severe hyperbilirubinemia can lead to kernicterus, which is preventable if the hyperbilirubinemia is identified early and treated appropriately. CONTENT: This review discusses neonatal jaundice and the use of transcutaneous bilirubin (TcB) measurements for identification of neonates at risk of severe hyperbilirubinemia. Such a practice requires appropriate serial testing and result interpretation according to risk level from a nomogram that provides bilirubin concentrations specific for the age of the neonate in hours. In this context, we have evaluated the potential impact on clinical outcome and limitations of TcB methods in current use. SUMMARY: TcB measurement is a viable option in screening neonates to determine if they are at risk for clinically significant hyperbilirubinemia. Total serum bilirubin should be measured by a clinical laboratory if a newborn is shown to be at higher risk for clinically significant hyperbilirubinemia. In addition, external quality assessment to identify biases and operator training issues should be part of any TcB monitoring program.",
author = "El-Beshbishi, {Samar N.} and Karen Shattuck and Mohammad, {Amin A.} and Petersen, {John R.}",
year = "2009",
month = "7",
day = "1",
doi = "10.1373/clinchem.2008.121889",
language = "English (US)",
volume = "55",
pages = "1280--1287",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "7",

}

TY - JOUR

T1 - Hyperbilirubinemia and transcutaneous bilirubinometry

AU - El-Beshbishi, Samar N.

AU - Shattuck, Karen

AU - Mohammad, Amin A.

AU - Petersen, John R.

PY - 2009/7/1

Y1 - 2009/7/1

N2 - BACKGROUND: Neonatal jaundice or hyperbilirubinemia is a common occurrence in newborns. Although most cases of neonatal jaundice have a benign course, severe hyperbilirubinemia can lead to kernicterus, which is preventable if the hyperbilirubinemia is identified early and treated appropriately. CONTENT: This review discusses neonatal jaundice and the use of transcutaneous bilirubin (TcB) measurements for identification of neonates at risk of severe hyperbilirubinemia. Such a practice requires appropriate serial testing and result interpretation according to risk level from a nomogram that provides bilirubin concentrations specific for the age of the neonate in hours. In this context, we have evaluated the potential impact on clinical outcome and limitations of TcB methods in current use. SUMMARY: TcB measurement is a viable option in screening neonates to determine if they are at risk for clinically significant hyperbilirubinemia. Total serum bilirubin should be measured by a clinical laboratory if a newborn is shown to be at higher risk for clinically significant hyperbilirubinemia. In addition, external quality assessment to identify biases and operator training issues should be part of any TcB monitoring program.

AB - BACKGROUND: Neonatal jaundice or hyperbilirubinemia is a common occurrence in newborns. Although most cases of neonatal jaundice have a benign course, severe hyperbilirubinemia can lead to kernicterus, which is preventable if the hyperbilirubinemia is identified early and treated appropriately. CONTENT: This review discusses neonatal jaundice and the use of transcutaneous bilirubin (TcB) measurements for identification of neonates at risk of severe hyperbilirubinemia. Such a practice requires appropriate serial testing and result interpretation according to risk level from a nomogram that provides bilirubin concentrations specific for the age of the neonate in hours. In this context, we have evaluated the potential impact on clinical outcome and limitations of TcB methods in current use. SUMMARY: TcB measurement is a viable option in screening neonates to determine if they are at risk for clinically significant hyperbilirubinemia. Total serum bilirubin should be measured by a clinical laboratory if a newborn is shown to be at higher risk for clinically significant hyperbilirubinemia. In addition, external quality assessment to identify biases and operator training issues should be part of any TcB monitoring program.

UR - http://www.scopus.com/inward/record.url?scp=67650088581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650088581&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2008.121889

DO - 10.1373/clinchem.2008.121889

M3 - Article

C2 - 19443565

AN - SCOPUS:67650088581

VL - 55

SP - 1280

EP - 1287

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 7

ER -